Delivering Wound Treatment with Superior Outcomes

Aedicell® is a regenerative medicine company that has developed a unique proprietary process to transform human tissue into biologics for therapy, focusing on the conversion of human placenta into two skin substitute products, Plurivest® and Dermavest®. 

The company’s mission is to deliver wound therapies for superior outcomes at a lower cost to the healthcare system by using rapid, advanced product development and manufacturing techniques.

Aedicell was founded by Ted Burke who has spent his career in the manufacturing and biotechnology industries.

A former manager at General Electric and director of manufacturing at Celgene Cellular Therapeutics, Ted is a Six Sigma Black Belt and skilled in process improvement and product development.